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cal limb ischemia (Fountain stage III-IV) at admission;
length of stay no less than 2 weeks; conservative manage-
ment before surgery for one week at least. Patient charac-
teristics, length of stay (LOS) and discharge status were
assessed. Amputation was considered as treatment fail-
ure. Direct medical costs for pharmacotherapy, diagnos-
tic and treatment services were calculated.
RESULTS: Mean age of patients was 63,8  11,46 years;
84,8% were men. Duration of critical limb ischemia before
admission varied from two weeks to 14 months. Mean LOS
was 31  14 days. From 1 to 41 drugs (12,9  8,6) were
prescribed to patients during hospitalization. Most fre-
quently used drugs were pentoxifyllin and rheopolygluci-
num (77,1% and 58% of patients). Amputation was per-
formed on 41,9% patients, and angioplasty on 32,4%.
Median cost of treatment in the study group was 35 462,70
rub (1 222.9$). The median cost for treating patients with
amputation was 41 698,41 rub (1437.9$), and the median
cost for patients with angioplasty was 43 802,3 rub
(1510.4$). Median cost for patients without surgical inter-
vention was significantly lower - 14 423,4 rub (497.4$).
CONCLUSION: Common practice treatment for critical
limb ischemia in Moscow hospitals requires amputation
in 41,9 % of cases. Costs for management patients with
amputation do not differ from costs for management of
patients requiring angioplasty when all direct costs are
taken into account.
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During the development of hypertension, a progressive in-
crease in left ventricular mass (LVM) occurs. This hyper-
trophy is a predictor of the incidence of cardiovascular
disease and mortality. The great majority of anti-hyperten-
sive drugs lead to a reduction of LVM, thus improving the
prognosis. It is not known, however, which of these drugs
is the most cost-effective in terms of reduction of LVM.
OBJECTIVE: To investigate the cost of reducing LVM
by 1 gram with various agents during the treatment of
hypertension.
METHODS: Out of 28 trials published between 1984
and 1995, only 17 were included (528 patients, 21 drugs
from main anti-hypertensive classes including ACE inhib-
itors, or drug combinations) because they were of 12
months duration. The cost of drugs used (at Polish prices)
for the treatment period was divided by the change in
LVM in grams during that period.
RESULTS: The most cost-effective drugs in terms of
LVM reduction (USD/gram of muscle) were: atenolol
0,11; prazosin 0,34; hydralazine 0,44. Combinations of
anti-hypertensives were highly cost-effective: rezerpine 
hydrochlorothiazide 0,11; atenolol  indapamide 0,92.
CONCLUSION: These results may serve as a guide in deci-
sion-making for the choice of treatment and reimbursement.
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OBJECTIVES: A Chest Pain Unit (CPU) with a diagnos-
tic algorithm employing troponin T (TnT) assay was im-
plemented in a public hospital in Hong Kong in February
2000. The aim of this study was to compare the cost-
effectiveness in risk stratification of chest pain (CP) pa-
tients before and after the implementation of a CPU from
the perspective of a public-health organization.
METHODS: Medical records of patients with CP pre-
sented to the Accident & Emergency (A&E) department in
November 1999 (pre-CPU) and November 2000 (post-
CPU) were reviewed. Patients with non-diagnostic CP
were recruited. Resource utilization for CP diagnosis was
retrieved from medical records. The clinical outcome (30-
day post-discharge re-admission or death secondary to car-
diac causes) was obtained from follow-up phone interview
and hospital records for patients discharged home from
A&E or CPU. Cost-effectiveness ratios (CERs) for the two
study periods and incremental CER were calculated.
RESULTS: There were 689 and 836 patients presented to
A&E with CP in November 1999 and November 2000,
respectively. The percentage of patients discharged from
A&E was higher in the pre-CPU group (64.7% vs.
50.5%, p  .001). A total of 529 patients in the pre-CPU
group and 581 patients in the pre-CPU group with non-
diagnostic CP were recruited. The cost of differential di-
agnosis for CP per patient was HK$2,934 (1USD  7.8
HKD) in the pre-CPU group and HK$3,641 in the post-
CPU group. The 30-day, post-discharge, cardiac-event
rate was 8.4% in pre-CPU group vs. 5.6% in post-CPU
group (p  .172). The CERs were HK$3,203 (pre-CPU)
and HK$3,857 (post-CPU) per patient per 30-day, car-
diac-event-free period. The incremental CER for the post-
CPU group was HK$25,245 per additional patient per
30-day, cardiac-event-free period.
CONCLUSION: Based on the data obtained, the imple-
mentation of a CPU appears to be able to reduce the 30-
day cardiac event rate with an incremental CER of
HK$25,245.
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OBJECTIVE: To evaluate the cost consequences of
LMWH compared with unfractionated heparin in the
treatment of unstable angina pectoris in Japan.
METHODS: A cost-consequence analysis was performed
using decision-analytic modeling using evidence from the
FRISC (Fragmin during Instability in Coronary Artery
Disease) study group, Sweden. The decision tree models a
patient presenting with unstable angina pectoris and fac-
ing the alternative treatments of LMWH or heparin as a
basic model. Also, an advanced model was constructed
with treatment options that reflected more realistic prac-
tice patterns in Japan. Cardiologists reviewed the model-
development process to make the model relevant to the
Japanese medical environment. The direct costs were ob-
tained from pilot studies of DRGs in Japanese national
hospitals.
RESULTS: In the basic model, we estimated a slight dif-
ference in expected costs between LMWH and heparin,
favoring LMWH. However, this model was limited in
two main areas: 1) difference in effects between LMHW
and heparin were not statistically significant in the FRISC
study; 2) opportunity costs such as monitoring for hep-
arinization and treatment of bleeding with heparin were
not included. When we incorporated realistic assump-
tions regarding the opportunity costs and Japan’s treat-
ment patterns, we found that the total medical costs for
the LMWH group were much lower than for the heparin
group even if the clinical effects for heparin and LMWH
were set as equal. In this case, the estimated cost in the
LMWH group was about $11,300 per patient and
$19,600 for the heparin group assuming LMWH is prop-
erly used in clinical practice. This result was robust to a
range of sensitivity analyses.
CONCLUSION: The use of LMWH for unstable angina
pectoris in actual clinical practice where heparin monitoring
can be avoided appears to be cost-saving in Japan. Consid-
ering the target population of 700,000 patients in Japan, the
LMWH will have a great economic impact on society.
PCV29
PERSISTENCY OF TREATMENT IN PATIENTS 
INITIATED ON FIVE DIFFERENT CLASSES OF 
ANTIHYPERTENSIVE THERAPY: 
A PHARMACO-UTILIZATION AND 
PHARMACO-ECONOMIC ANALYSIS
Valpiani G1, Degli Esposti L1, Saragoni S1, Degli Esposti E2
1CliCon Srl - Health, Economics and Outcomes Research, 
Ravenna, Italy; 2 Health Directorate, Ravenna Local Health Unit, 
Ravenna, Italy
OBJECTIVE: To quantify and qualify the antihyperten-
sive pharmaceutical expenditure incurred for the treat-
ment of a population in the real world.
METHODS: An administrative database, collecting in-
formation on all purchased drugs, was used to perform a
retrospective analysis for each health-assisted subject by
the Ravenna Local Health Unit. By crosschecking with
the registry office and hospital database, gender, age and
previous hospitalizations for cardiovascular diseases were
also made available. All new users over 20 years old re-
ceiving a first prescription for diuretic, beta-blocker, cal-
cium-channel-blocker, angiotensin-converting-enzyme in-
hibitor or angiotensin II antagonist between 01/01/1997
and 12/31/1997 were included. According to persistency
of treatment, patients were classified as continuers (dura-
tion of therapy over 273 days with the initial antihyper-
tensive class), switchers (duration of therapy over 273
days with a different class of antihypertensive than origi-
nally prescribed) and discontinuers (duration of therapy
less than 273 days). The follow-up period lasted 365
days.
RESULTS: A total of 16,783 patients were enrolled, in-
cluding 7409 men (44.1%) and 9374 women (55.9%)
with an average age of 56.1  18.3 years. Continuers
and switchers represented 26.9% and 8.2% of enrolled
subjects, respectively. The percentage of treatment inter-
ruptions (64.9%) ranged from 42.0% with angiotensin II
antagonists to 69.8% with diuretics, and 53.8% of the
population interrupted therapy after the first prescrip-
tion. Age, co-morbidities and previous hospitalizations were
higher for continuers and switchers than for discontinu-
ers. The overall expenditure accounted for €1,076,053.55
of which 54.8% was for continuers, 19.8% for switchers
and 25.4% for discontinuers. The percentage of the over-
all cost for discontinuers ranged from 14.8% with angio-
tensin II antagonists to 30.6% with calcium-channel
blockers.
CONCLUSION: The high percentage of discontinuers
translated into an expense incurred improperly. The high
percentage of interruptions after the first prescription
seemed to indicate that medication prescribed at enroll-
ment was not appropriate.
PCV30
A POPULATION-BASED EUROPEAN STUDY OF 
PERSISTENCE IN NEWLY DIAGNOSED 
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Patients’ persistence with chronic treatment is a major
component in the effectiveness assessment.
OBJECTIVE: To evaluate whether the initial choice of
antihypertensive agent impacts newly diagnosed hyper-
tensive patients’ persistence with treatment at one year.
METHODS: The comparisons were between patients ini-
tially prescribed irbesartan, angiotensin II receptor antag-
onists (AIIRA) versus other antihypertensive drugs. We
compared the proportion of patients who remained on
the monotherapy initially prescribed, added to their ini-
tial therapy, switched to another therapy, or discontinued
therapy at one year using chi-squared tests. Monotherapy
